Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial

This study has been completed.
Sponsor:
Collaborators:
Minnesota Veterans Research Institute
InterMune
Kadmon Pharmaceuticals
San Diego Veterans Healthcare System
Information provided by (Responsible Party):
Samuel B. Ho, Minneapolis Veterans Affairs Medical Center
ClinicalTrials.gov Identifier:
NCT00211692
First received: September 13, 2005
Last updated: November 20, 2014
Last verified: November 2014
Results First Received: August 1, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Chronic Hepatitis C
Interventions: Drug: consensus interferon (Interferon Alfacon-1) and ribavirin
Drug: Consensus Interferon alfa (CIFN) and ribavirin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients with difficult-to-treat characteristics (78% VA) were enrolled at 7 Veterans Affairs (VA) and 2 community medical centers.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
All eligible patients were randomized and analysis performed using intention to treat.

Reporting Groups
  Description
Group A 52 Weeks Treatment Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)
Group B Duration Based on Viral Response CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)

Participant Flow:   Overall Study
    Group A 52 Weeks Treatment     Group B Duration Based on Viral Response  
STARTED     33     31  
COMPLETED     33     31  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Group A 52 Weeks Treatment Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)
Group B Duration Based on Viral Response CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)
Total Total of all reporting groups

Baseline Measures
    Group A 52 Weeks Treatment     Group B Duration Based on Viral Response     Total  
Number of Participants  
[units: participants]
  33     31     64  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     33     31     64  
>=65 years     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  51.4  ± 8.0     49.8  ± 8.8     50.6  ± 8.4  
Gender  
[units: participants]
     
Female     1     3     4  
Male     32     28     60  
Race (NIH/OMB)  
[units: participants]
     
American Indian or Alaska Native     0     0     0  
Asian     0     0     0  
Native Hawaiian or Other Pacific Islander     0     0     0  
Black or African American     11     10     21  
White     22     19     41  
More than one race     0     0     0  
Unknown or Not Reported     0     2     2  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Primary Endpoint Would be the Number Who Achieve a Sustained Virologic Response.   [ Time Frame: 24 weeks after the end of treatment ]

2.  Secondary:   Number of Participants Discontinuing Early From Study Treatment   [ Time Frame: through end of study up to 72 weeks ]

3.  Secondary:   Participants Achieving SVR Categorized by Time of Response   [ Time Frame: 24 weeks after end of treatment ]

4.  Secondary:   Overall Number of Serious Adverse Events   [ Time Frame: through end of study up to 72 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Samuel B. Ho, MD, Chief GI Section
Organization: VA San Diego Healthcare System
phone: 858-552-8585 ext 2631
e-mail: samuel.ho2@va.gov


Publications of Results:

Responsible Party: Samuel B. Ho, Minneapolis Veterans Affairs Medical Center
ClinicalTrials.gov Identifier: NCT00211692     History of Changes
Other Study ID Numbers: MVRI001
Study First Received: September 13, 2005
Results First Received: August 1, 2011
Last Updated: November 20, 2014
Health Authority: United States: Food and Drug Administration